Tejasav Sehrawat

Tejasav Sehrawat, MD, is a researcher and clinician affiliated with the Yale School of Medicine, Department of Internal Medicine. His work focuses on hepatology, immunology, and translational medicine, with a particular emphasis on alcoholic liver disease, portal hypertension, and extracellular vesicles as diagnostic/prognostic biomarkers. He has contributed to studies on sphingosine 1-phosphate signaling, chemokine biology, and liver fibrosis mechanisms. Dr. Sehrawat holds editorial roles at Frontiers in Immunology and Frontiers in Medicine, and has received prestigious awards including the Yale International Physician-Scientist Resident and Fellow Award (2023) and the Young Investigator Award (2019). His research bridges basic science and clinical applications, addressing critical gaps in understanding and treating liver diseases.

Education and Training: Completed residency in Internal Medicine at Yale School of Medicine, with affiliations to the Slayman House. His academic background includes advanced training in both clinical practice and research methodologies.

Research Interests: Dr. Sehrawat’s studies investigate molecular pathways driving liver injury, including the role of chemokines (e.g., CXCL1), extracellular vesicle cargo, and mechanotransduction in sinusoidal endothelial cells. His work also explores biomarkers for diagnosing and monitoring conditions like alcoholic hepatitis and nonalcoholic steatohepatitis (NASH).

Publications: Over 40 peer-reviewed articles, with contributions to high-impact journals such as Hepatology, Nature Communications, and Nature Reviews Gastroenterology & Hepatology. Recent work includes advancements in sphingosine receptor modulation and epigenetic regulation of liver diseases.

Awards: Recognized for early-career contributions in both clinical and basic science domains, emphasizing his dual focus on physician-scientist roles.